Peanut Allergy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Peanut Allergy – Drugs In Development, 2024 report and make more profitable business decisions.
Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions such as hives, redness or swelling; itching or tingling in or around the mouth and throat; digestive problems, such as diarrhea, stomach cramps, nausea or vomiting; tightening of the throat; shortness of breath; or wheezing and runny nose.
The Peanut Allergy drugs in development market research report provide comprehensive information on the therapeutics under development for Peanut Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Peanut Allergy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 39 molecules, with 33 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Peanut Allergy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Peanut Allergy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Peanut Allergy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
ALK-Abello ASAllakos Inc
Allergy Therapeutics Plc
Amgen Inc
Angany Inc
Aravax Pty Ltd
AstraZeneca Plc
BioLingus AG
BlueWillow Biologics Inc
Cambridge Allergy Ltd
Cour Pharmaceuticals Development Co Inc
DBV Technologies SA
F. Hoffmann-La Roche Ltd
General Nutraceutical Technology LLC
GI Biome Inc
IgGenix Inc
Immunomic Therapeutics Inc
Inimmune Corp
InnoUp Farma SL
Intrommune Therapeutics Inc
Johns Hopkins University
Mabylon AG
Moonlight Therapeutics Inc
National Jewish Health
Nestle Health Science
Novartis AG
Phlaxis
Prota Therapeutics Pty Ltd
Sementis Ltd
Stallergenes Greer Ltd
Stanford University
The Scripps Research Institute
Ukko Inc
University of Notre Dame
Vedanta Biosciences Inc
Virtici LLC
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Peanut Allergy reports